European and UK doctors review latest studies on HIV and COVID-19 coinfection
On 5 August 2020, a joint statement by leading European HIV medical organisations reviewed the most recent research on COVID-19, especially in relation to HIV coinfection and news on latest treatment.
These monthly reviews are compiled by leading doctors from BHIVA, DAIG (Germany), EACS, GESIDA (Spain) & the Polish Scientific AIDS Society and include editorial commentary on the studies covered.
The review is included below, with references available from the link on the BHIVA website.
Statement on risk of COVID-19 for people living with HIV
BHIVA, DAIG (Germany), EACS, GESIDA (Spain) & the Polish Scientific AIDS Society
COVID-19 & HIV
Case series of people living with HIV (PLWH) with COVID-19 have been published from China, Spain, Germany, Italy and the United States (1-15) with no clear evidence for a higher COVID-19 infection rate or different disease course in people with and without HIV. Of note, most case series of PLWH report a younger age in their study population than in HIV-negative hospitalised COVID-19 patients, but comparable rates of comorbidities.
In a cohort study from the United Kingdom a small potential increase in the risk of mortality among PLWH once hospitalised with COVID-19 was reported at the July 2020 BHIVA conference, albeit with no data around the risk of developing severe COVID-19 or hospitalisation among this cohort in the first place and no data on antiretroviral therapy (ART), viral load (VL) or CD4 count. 
More recently an analysis of risk factors for COVID-19 deaths in the Western Cape was presented at the virtual AIDS 2020 conference . After adjusting for other risk factors, they found HIV increased a COVID-19 patient’s death risk by a factor of 2.14 (95% CI 1.70;2.70), and active TB by a factor of 2.70 (95% CI 1.91.4.04). The larger prevalence of HIV in Africa permits study of higher participant numbers but there may be differences in baseline characteristics compared to populations from Western Europe or China with regard to other risk factors for mortality including age, concomitant comorbidities, obesity rate and socioeconomic status (the latter two were not captured in this data set)
Finally, in the Annals of Internal Medicine, Spanish researchers described the incidence of COVID-19 and risk of hospitalization among 77,590 PLWH receiving ART . During a 3-month period, 236 PLWH were diagnosed with COVID-19, and 151 were hospitalized. The risk of hospitalization by NRTI treatment per 10,000 persons was lowest for TDF/FTC (10.5), while other NRTI strategies were similar (TAF/FTC 20.3, ABC/3TC 23.4, single or no NRTI 20.0) ; TDF/FTC recipients also had a lower overall incidence of infection and none died or were admitted to the intensive care unit . Noteworthy, PLWH remaining on TDF/FTC today are less likely to have some of the medical comorbidities associated with worse COVID-19 outcomes . Older PLWH, in particular those with renal or cardiovascular disease, increasingly receive either TAF/FTC or just 3TC as NRTI backbone . A recently published further analysis of the Spanish cohort suggests that confounding due to unmeasured clinical characteristics does not completely explain the association between TDF/FTC and a lower COVID-19 diagnosis and hospitalization . Nevertheless, the somewhat diverse observations ranging from potentially improved outcome on TDF/FTC to two-fold increased mortality risk associated with HIV clearly underline the need for additional data from larger cohorts.
Current evidence indicates that the risk of severe COVID-19 illness increases with age, male gender and with certain chronic medical problems such as arterial hypertension, cardiovascular disease, chronic lung disease, obesity and diabetes. Whether or not PLWH on treatment with a normal CD4 count and suppressed VL are at an increased risk of serious illness or death, many will have other conditions that increase their risk. Indeed, almost half PLWH in Europe are older than 50 years and chronic medical conditions, including cardiovascular and chronic lung disease, are more common in PLWH. As a risk factor for respiratory infections smoking cessation should be encouraged for all. Influenza and pneumococcal vaccinations should be kept up to date as recommended by BHIVA/EACS guidelines.
Despite the lack of evidence for an association between HIV surrogate markers and COVID-19 mortality in the Western Cape data, we continue to advise that immune suppression, indicated by a low CD4 (<200 cells/mm3), or not receiving ART, should be considered a risk factor. Data in such PLWH is sparse as so far most COVID-19 patients with HIV have been on suppressive ART. For PLWH with low CD4 counts (<200 cells/mm3), or who experience a CD4 decline during a COVID-19 infection, remember to initiate opportunistic infection (OI) prophylaxis. This is not aiming at preventing a more severe course of COVID-19 but rather complications through additional OIs. More information regarding recommendations for prophylaxis and treatment of specific opportunistic infections can be found in the BHIVA/EACSguidelines for HIV/AIDS.
The ongoing discussion about potential COVID-19 vertical transmission remains controversial. Although few case reports have claimed perinatal transmission several other large case series could not find any case of vertical transmission [21-25]. Pregnant women with critical COVID-19 who deliver during their disease course mostly deliver preterm via caesarean section . Although the majority of mothers have been discharged without any major complications, severe maternal morbidity as a result of COVID-19 and perinatal deaths have been reported. Careful monitoring of pregnancies with COVID-19 and measures to prevent neonatal infection are warranted.
Existing national guidelines should be followed in terms of reducing risk for acquiring a COVID-19 infection and managing symptoms [26-29].
COVID-19 treatment: antiretrovirals
Expedited research and publication are welcomed with the caveat that results may be disseminated pre-publication and/or published without usual peer review. There is ongoing discussion and research around some ARVs that might have some activity against COVID-19. The first randomised clinical trial (RCT) with lopinavir-ritonavir (LPV/r) started a median of 13 days after symptom onset and demonstrated no benefit over standard care in 199 hospitalised adults with severe COVID-19 . Since then the large UK RECOVERY trial, which to date has randomised almost 12,000 people hospitalised with COVID-19 to different therapeutic options, has stopped recruitment to the LPV/r arm after a review by Data Monitoring Committee revealed no benefit of LPV/r over standard of care in terms of mortality, ventilation requirement or length of stay . There is no evidence to support the use of other ARVs, including PIs; indeed, structural analysis demonstrates no darunavir (DRV) binding to COVID-19 protease. Moreover, an Italian case series suggests boosted DRV does not prevent SARS-CoV-2 infection in PLWH or protect against worsening respiratory function, at least not at a dose of 800 mg daily .
Data regarding the activity of TDF against SARS CoV-2 is conflicting. In Silico data suggests that TDF/FTC may bind to SARS CoV-2 Nsp1 protein , an unreviewed study shows that TDF and TAF may inhibit the SARS-CoV-2 polymerase , one in vitro study supports antiviral activity of TDF/FTC  and an animal models suggest shortened duration of symptoms, and possibly infectiousness . However, two studies have failed to demonstrate any in vitro activity of tenofovir against CoV-2 [37, 38] so more data is required.
Currently, a large randomised phase 3 placebo-controlled study in Spain using the HIV pre-exposure prophylaxis (PrEP) combination TDF/FTC and low-dose hydroxychloroquine (HCQ) as prophylaxis for COVID-19 in health workers is planned , but the clinical trial results have to be awaited to shed light on the usefulness of this PrEP strategy.
Currently, no evidence is available to justify switching PLWH from their usual ART. Additionally, there is no evidence to support HIV-negative people taking ARVs outside the context of PrEP to prevent HIV acquisition – PrEP should be taken as directed and there is no current evidence that PrEP is effective against COVID-19.
CCR5-inhibitors, in particular maraviroc (MVC,) have also been suggested to have antiviral properties against SARS-CoV-2. Indeed, the binding pattern of MVC has suggested a strong binding to the pocket of SARS-CoV-2 main protease (Mpro) which could result in strong inhibition and prevention of infection . MVC also binds in between the domain I and II where the substrate-binding site is located and forms a significant number of interactions to the critically important residues of SARS-CoV-2 Mpro . Moreover, CCR5 antagonism prior to the ‘second wave’ of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and alter inflammatory cell trafficking, both increasing viral control capacity and dampening damage to lung tissue, respectively. Clinical trials are underway to establish whether one week of treatment with MVC, used at its approved dosage to treat HIV, is safe and tolerable in patients with SARS-CoV-2.
PRO 140 (leronlimab) is a humanized monoclonal antibody targeted against the CCR5 receptor found on human T lymphocytes under investigation as a potential HIV therapy. More recently, laboratory data from persons treated with leronlimab for COVID-19 infection has shown increases in the profoundly decreased CD8 T-lymphocyte percentages by Day 3, normalization of CD4/CD8 ratios, and resolving cytokine production including reduced IL-6 correlating with clinical improvement . The current data suggests a trend toward the restoration of immune function by day 7. Restoration of the immune function is critical in COVID-19 patients to prevent other infections.
COVID-19 treatment: other options
A case series on HCQ, with or without azithromycin, was not able to demonstrate a clear clinical benefit, despite in vitro inhibition of SARS-CoV-2, due to methodological issues ; although the same group postulated an infection control benefit of more rapid viral clearance there was a lack of control arm for comparison . One small RCT demonstrated trends for reduced time to clinical recovery and short-term radiological improvement for HCQ , though another showed no benefit in terms of viral clearance, clinical or radiological endpoints . A recently published retrospective analysis of patients hospitalised with confirmed SARSCoV-2 infection in all US Veterans Health Administration medical centres found no evidence that use of HCQ, with or without azithromycin, reduced the risk of mechanical ventilation and even found an association of increased overall mortality in patients treated with HCQ alone . Subsequently, two further observational studies showed no impact of HCQ, azithromycin, or both, on in-hospital mortality and/or intubation rates [47,48]. Finally, the Recovery trial, stopped its HCQ arm due to “no evidence of benefit”  based on 28-day mortality rates of 25.7% and 23.5% in the HCQ and usual care arms, respectively. In addition to lack of efficacy, the study has flagged important safety concerns including cardiac arrhythmias on HCQ or chloroquine and methaemoglobinaemia on HCQ .
The first successfully licensed drug for COVID-19 treatment is remdesivir, originally developed for Ebola therapy, which has broad in vitro antiviral activity against SARS-CoV-2 . First cases from the expanded access program using remdesivir for COVID-19 patients suggested potential clinical benefit . The first RCT from China demonstrated that remdesivir was not associated with statistically significant clinical benefits in adults with severe COVID-19 , indeed remdesivir was stopped early in 18 (12%) patients because of adverse effects, compared with 4 (5%) in the control group . Of note, the study was stopped early due to low patient enrolment which may limit its power. Finally, data on remdesivir from the Adaptive COVID-19 Treatment Trial (ACTT) was presented, in which 1,063 hospitalised patients with advanced COVID-19 and lung involvement who were randomised to remdesivir recovered faster than similar patients who received placebo, with a median recovery time to 11 days and 15 days, respectively . Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059) . Meanwhile the SIMPLE study showed that a five-day dosing duration of remdesivir led to “similar improvement in clinical status” as the 10-day treatment course being evaluated in the NIAID study and other ongoing trials . An expansion phase of the SIMPLE study has been added and will enrol an additional 5,600 patients, including patients on mechanical ventilation.
A further agent under investigation for COVID-19 treatment is famotidine. Following the observation of lower mortality amongst hospitalised COVID-19 patients on famotidine , a small single-arm study described improved patient reported outcomes in non-hospitalised COVID-19 patients starting famotidine . Retrospective chart data patients hospitalized with COVID-19 in New York showed that famotidine use was associated with a reduced risk of clinical deterioration leading to intubation or death . A RCT is currently underway to determine whether famotidine can improve clinical outcomes in hospitalized COVID-19 patients (NCT04370262). A further agent under investigation for COVID-19 treatment is famotidine. Following the observation of lower mortality amongst hospitalised COVID-19 patients on famotidine , a small single-arm study described improved patient reported outcomes in non-hospitalised COVID-19 patients starting famotidine . Retrospective chart data patients hospitalized with COVID-19 in New York showed that famotidine use was associated with a reduced risk of clinical deterioration leading to intubation or death . A RCT is currently underway to determine whether famotidine can improve clinical outcomes in hospitalized COVID-19 patients (NCT04370262).
A recent study reported that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells . It has been emphasized however, that the laboratory results showing efficacy of ivermectin to reduce viral loads in laboratory cultures, at dosage levels far beyond those approved by the FDA for treatment of parasitic diseases in humans, are not sufficient to indicate that ivermectin will be of clinical benefit to reduce viral loads in COVID-19 patients. Chaccour et al. caution against using in vitro findings as more than a qualitative indicator of potential efficacy and emphasise that due diligence and regulatory review are needed before testing ivermectin in COVID-19 .
Finally, first data from a meta-analysis of trials from Iran studying the therapeutic effects of the HCV direct acting antivirals sofosbuvir and daclatasvir have been presented at the AIDS 2020 virtual conference suggesting a potential mortality benefit from this treatment intervention . Not all included data was derived from RCTs, and the overall number of treated patients was low; larger studies are currently underway.
The full results from these trials, as well as other ongoing clinical trials especially in early COVID-19 disease, are eagerly awaited. A list of currently ongoing or planned COVID-19 studies in PLWH can be found under: https://www.clinicaltrials.gov/ct2/results?term=hiv+covid&Search=Search
Maintaining HIV care during the COVID-19 pandemic
Implementation of quarantine, social distancing, and community containment measures have reduced access to routine HIV testing, which challenges completion of UNAIDS’ first 90-90-90 target globally . Moreover, timely linkage to HIV care as well as ART continuation, will be hindered during the COVID-19 pandemic, as physicians from HIV-clinics are sharing HIV care and COVID-19 care duties as recently demonstrated from the Euro Guidelines in Central and Eastern Europe (ECEE) Network Group for more than 50% of clinics in central and Eastern Europe . In many countries with high COVID-19 case load there is a need to prepare for operating under minimal medical resources with the aim to secure retention on ART. Non-governmental organisations are needed to second medical efforts to ensure the continuity of ART deliverance for treatment and prevention.
COVID-19 data collection & resources
A COVID-19 drug interactions website (www.covid19-druginteractions.org) has been developed for the experimental drugs being trialed to treat COVID-19 in different parts of the world. EACS and BHIVA are happy to announce that they have agreed to financially support this very useful website. A useful Spanish interaction resource is also available as a PDF: http://www.interaccionesvih.com/docs/Interacciones%20importantes%20con%20Kaletra%20e%20Hidroxicloroquina_20%20marzo%202020_COVID.pdf. (PDF)
We would like to highlight three resources for reporting COVID-19 cases:
- The NEAT ID Foundation has developed a ‘data dashboard’ to monitor COVID-19 case numbers, hospitalisations and mortality in people with HIV and/or hepatitis at European and country level. The data will be available for public viewing via NEAT-ID.organd if your centre has not signed up, you can do so via this link.
- The Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS) launched by the German Society for Infectious Diseases (DGI) and ESCMID’s Emerging Infections Task Force (EITaF) an open register based on anonymous questionnaires and they are keen to collaborate with other registries. See https://leoss.net, contact them by email at email@example.com.
The register can be accessed here https://leoss.net/statistics
- EASL is supporting a registry which can be found under the following link https://www.covid-hep.net
The coronavirus outbreak is rapidly evolving. EACS, BHIVA, DAIG, GESIDA and the Polish Scientific AIDS Society will continue to share any updates to specific guidance for PLWH. Wishing you all well. Stay healthy.
Source and references
BHIVA, DAIG, EACS, GESIDA & Polish Scientific AIDS Society Statement on risk of COVID-19 for people living with HIV (PLWH). (5 August 2020).
This article was originally posted on 5 August 2020.